There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY) and Strongbridge Biopharma Plc (SBBP) with bullish sentiments.
Alnylam Pharma (ALNY)
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Alnylam Pharma, with a price target of $147. The company’s shares closed yesterday at $83.03.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.7% and a 51.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $128 average price target, representing a 54.2% upside. In a report issued on April 26, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $138 price target.
See today’s analyst top recommended stocks >>
Strongbridge Biopharma Plc (SBBP)
Oppenheimer analyst Hartaj Singh maintained a Buy rating on Strongbridge Biopharma Plc yesterday and set a price target of $15. The company’s shares closed yesterday at $3.79, close to its 52-week low of $3.70.
Singh noted:
“On 05/01, Strongbridge reported 1Q19 results and provided a corporate update. Notably, the company finalized its regulatory strategy with Type- C meeting with the FDA. SBBP plans to file the Recorlev NDA for Cushing’s following results of its second ongoing Phase 3 LOGICS study. While one may debate whether this timeline reflects a slight delay to an upside case or an acceleration to a base case, we believe the clear timeline and path for Recorlev’s entry to the Cushing’s market (potentially 2021) creates a compelling buying opportunity for investors. A recent KOL call we hosted has also added to our confidence in the Recorlev opportunity, which is nearing the horizon. We update our model for the quarter and stay bullish.”
According to TipRanks.com, Singh is a 3-star analyst with an average return of 1.9% and a 42.5% success rate. Singh covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Strongbridge Biopharma Plc with a $13.75 average price target, implying a 262.8% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $9 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
